ChartMill assigns a Buy % Consensus number of 81% to IRD. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-10 | B. Riley Securities | Initiate | Buy |
| 2025-11-25 | Piper Sandler | Initiate | Overweight |
| 2025-11-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-10-29 | Wedbush | Initiate | Outperform |
| 2025-10-16 | Chardan Capital | Initiate | Buy |
| 2025-06-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-17 | LUCID CAPITAL MARKETS | Initiate | Buy |
| 2025-04-11 | Craig-Hallum | Initiate | Buy |
| 2025-04-01 | Jones Trading | Maintains | Buy -> Buy |
| 2025-04-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
14 analysts have analysed IRD and the average price target is 7.96 USD. This implies a price increase of 264.95% is expected in the next year compared to the current price of 2.18.
The consensus rating for OPUS GENETICS INC (IRD) is 81.4286 / 100 . This indicates that analysts generally have a positive outlook on the stock.